EMPAGLI MET 12.5+500 TABLET

EMPAGLI MET 12.5+500 TABLET is a combination medication that contains two active ingredients: Empagliflozin (12.5mg) and Metformin (500mg). It is primarily used in the treatment of type 2 diabetes mellitus to help control blood sugar levels.

1. Empagliflozin: Empagliflozin belongs to a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It works by inhibiting the reabsorption of glucose in the kidneys, leading to increased urinary glucose excretion and lowered blood sugar levels. It helps improve glycemic control and reduces the risk of cardiovascular events in individuals with type 2 diabetes.
2. Metformin: Metformin is a medication classified as a biguanide. It works by reducing glucose production in the liver, decreasing intestinal glucose absorption, and increasing insulin sensitivity in the body’s tissues. Metformin is commonly used as an oral antidiabetic drug to manage blood sugar levels in individuals with type 2 diabetes.

Empagli Met 12.5+500mg Tablet combines the mechanisms of action of both empagliflozin and metformin to provide synergistic effects in controlling blood glucose levels.

Side Effects

Empagli Met 12.5+500mg Tablet may cause side effects in some individuals. Common side effects associated with this medication include:

1. Genital yeast infections: Empagliflozin, as an SGLT2 inhibitor, can increase the risk of genital yeast infections in both men and women.
2. Urinary tract infections: Empagliflozin may increase the likelihood of urinary tract infections due to increased urinary glucose excretion.
3. Hypoglycemia: Although metformin is not typically associated with hypoglycemia, the combination with empagliflozin may slightly increase the risk of low blood sugar levels, especially when used in conjunction with other diabetes medications.
4. Gastrointestinal effects: Metformin can cause gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort.
5. Dehydration: Empagliflozin can increase urine output, which may lead to dehydration if adequate fluid intake is not maintained.

It is important to note that not all individuals will experience these side effects, and the occurrence and severity may vary. If you experience persistent or severe side effects, it is advisable to consult your healthcare provider.

When Not to Use

There are certain situations when it is recommended to avoid using Empagli Met 12.5+500mg Tablet or any medication containing empagliflozin and metformin. These include:

1. Allergies: If you have a known allergy or hypersensitivity to empagliflozin, metformin, or any other ingredients in the medication, it is important to avoid using Empagli Met 12.5+1000mg Tablet.
2. Renal impairment: Empagli Met 12.5+500mg Tablet is not recommended in individuals with severe kidney impairment or end-stage renal disease. Dose adjustment or alternative treatment options may be necessary.
3. Diabetic ketoacidosis: Empagli Met 12.5+500mg Tablet should not be used in individuals with diabetic ketoacidosis, a serious complication of diabetes characterized by high blood sugar levels and ketone buildup.
4. Dehydration: The use of Empagli Met 12.5+500mg Tablet should be avoided or used with caution in individuals at risk of dehydration, such as those with severe infections, vomiting, or diarrhea.